AIBODY partners with German Heart Center Berlin to revolutionize the diagnosis and treatment of congenital heart disease

LONDON–(BUSINESS WIRE)–A BODYthe world’s first Physiology-as-a-Service platform, today announced the signing of a collaboration agreement with the German Heart Center Berlin (DHZB), a leading medical research institute specializing in cardiovascular disease. This agreement covers the development of a suite of innovative solutions that will facilitate the diagnosis and treatment of congenital heart disease.

The collaboration will use AIBODY’s digital human physiology engine to create a realistic and highly detailed 3D and 4D model of a beating human heart, capable of reproducing the wide range of cardiovascular pathologies seen in patients with congenital heart defects. Informed by clinical data shared by the DHZB Cardiology team, the model will become a dynamic learning resource for clinician practitioners and trainees around the world, including cardiologists, pediatricians and radiologists, expanding their practical knowledge of congenital heart defects and helping them more effectively recognize these conditions in real patients.

Upon completion of the educational resource, AIBODY will proceed with the development of AI tools that will automatically extract features from cardiac ultrasounds to create an anatomically accurate “digitally matched” 3D and 4D model of a patient’s heart, providing aid in diagnosis physicians and radiologists to optimize personalized diagnosis and treatment for each patient.

“We will start by creating a comprehensive catalog of conditions to provide a ‘living’ reference guide for physicians and radiologists to help recognize and define what they see on patient imaging,” said Richard Littlehales, CEO from AIBODY. “Our ultimate goal is to build an AI-powered diagnostic device based on creating a ‘digital twin’ of each patient’s heart, reflecting their actual physiology and giving clinical teams a better understanding of the specific condition. of this patient and his likely course over time.”

“By combining our clinical knowledge and experience with the advanced simulation technology that AIBODY brings to the table, we will improve our ability to diagnose and treat patients, leading to better outcomes for patients around the world,” said said Professor Stanislav Ovrutsky, senior consultant at the DHZB clinic for congenital heart defects and pediatric cardiology. “Our first product will be a dynamic clinical reference guide that doctors can access on their phones or tablets. We expect this to be ready within a year.

About AIBODY

AIBODY is a cloud-based physiology-as-a-service platform that offers real-time, immersive medical simulations using the world’s first digital human organism. AIBODY’s unique approach produces highly detailed and realistic physiological responses to virtually any simulated medical condition or treatment protocol, recreating interrelated biophysical, physiological and biochemical processes occurring within a human body. AIBODY was born from AUGUST Global, the international technology group, and raised a round of seed funding from leading global venture capital firms. For more information, please visit www.aibody.io.

About the German Heart Center Berlin

The German Heart Center Berlin (Deutsches Herzzentrum Berlin) is an internationally renowned hospital and medical research center specializing in the treatment of cardiovascular and thoracic diseases, the implantation of mechanical circulatory support systems and heart and lung transplantation. For more information, please visit www.dhzb.de.